Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type



Status:Completed
Conditions:Alzheimer Disease, Neurology, Neurology, Neurology, Psychiatric, Psychiatric
Therapuetic Areas:Neurology, Psychiatry / Psychology
Healthy:No
Age Range:55 - 90
Updated:5/19/2018
Start Date:September 2013
End Date:March 2017

Use our guide to learn which trials are right for you!

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Flexible Dosing of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

To compare the efficacy of flexible dosing of brexpiprazole with placebo in subjects with
agitation associated with dementia of the Alzheimer's type

Behavioral symptoms, such as agitation, are core features in subjects with Alzheimer's
disease and related dementias and develop in the majority of dementia subjects. The presence
of agitation in subjects with Alzheimer's disease places a significant burden not only on
subjects and their caregivers but also on the healthcare system.

This is a trial designed to assess the safety and efficacy of flexible dosing of
brexpiprazole in the treatment of subjects with agitation associated with dementia of the
Alzheimer's type. The trial consists of a 12-week double-blind treatment period with a 30-day
follow-up. The trial population will include male and female subjects between 55 and 90 years
of age (inclusive) with a diagnosis of probable Alzheimer's disease, who are residing either
in an institutionalized setting or in a non-institutionalized setting where the subject is
not living alone.

Inclusion Criteria:

- Male and female subjects 55 to 90 years of age, inclusive, at the time of informed
consent.

- Subjects who are residing at their current location for at least 14 days before
screening and are expected to remain at the same location for the duration of the
trial.

- Subjects with diagnosis of probable Alzheimer's disease according to NINCDS-ADRDA
criteria.

- Subjects with a MMSE score of 5 to 22, inclusive, at screening and baseline visits.

- Subjects with onset of symptoms of agitation at least 2 weeks prior to the screening
visit.

- Subjects with a total score greater than or equal to 4 on the agitation aggression
item of the NPI-NH or NPI/NPI-NH at the screening and baseline visits.

- Subjects who require pharmacotherapy for the treatment of agitation per the
investigator's judgement, after an evaluation of reversible factors (eg, pain,
infection, polypharmacy) and a trial of nonpharmacological interventions.

- Subjects must have a previous MRI or CT scan of the brain, which was performed after
the onset of symptoms of dementia, with findings consistent with the diagnosis of
Alzheimer's disease.

Exclusion Criteria:

- Subjects with dementia or other memory impairment not due to Alzheimer's disease.

- Subjects with history of stroke, well-documented transient ischemic attack, or
pulmonary or cerebral embolism.

- Subjects who currently have clinically significant neurological, hepatic, renal,
metabolic, hematological, immunological, cardiovascular, pulmonary, gastrointestinal,
or psychiatric disorders.

- Subjects who have been diagnosed with an Axis I disorder (DSM-IV-TR criteria).

- Subjects with uncontrolled hypertension.

- Subjects with uncontrolled insulin-dependent diabetes mellitus (IDDM)

- Subjects with epilepsy or a history of seizures.

- Subjects considered in poor general health based on the investigator's judgment.
We found this trial at
25
sites
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Austin, TX
Click here to add this to my saved trials
?
mi
from
Bradenton, FL
Click here to add this to my saved trials
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
?
mi
from
Burgas,
Click here to add this to my saved trials
Charlotte, North Carolina 28207
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
?
mi
from
Imperial, CA
Click here to add this to my saved trials
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Lakewood, CA
Click here to add this to my saved trials
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
?
mi
from
Orange City, FL
Click here to add this to my saved trials
?
mi
from
Panorama City, CA
Click here to add this to my saved trials
?
mi
from
Quincy, MA
Click here to add this to my saved trials
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
?
mi
from
Smyrna, GA
Click here to add this to my saved trials
?
mi
from
South Dartmouth, MA
Click here to add this to my saved trials
555 Universal Hollywood Drive
Universal City, California 91950
?
mi
from
Universal City, CA
Click here to add this to my saved trials
?
mi
from
Woodstock, VT
Click here to add this to my saved trials